Last reviewed · How we verify
Biological vaccine
A biological vaccine that stimulates the immune system to recognize and attack disease-causing pathogens or abnormal cells.
At a glance
| Generic name | Biological vaccine |
|---|---|
| Sponsor | Inmunotek S.L. |
| Drug class | Vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Biological vaccines work by presenting antigens (foreign proteins or molecular patterns) to the immune system, triggering both innate and adaptive immune responses. This leads to the generation of antibodies and T-cell mediated immunity, enabling the body to mount a protective or therapeutic response against the target pathogen or disease. Inmunotek's vaccine candidates typically employ immunological principles to enhance immune recognition and elimination of their targets.
Approved indications
Common side effects
- Injection site reactions
- Fever
- Fatigue
Key clinical trials
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer (PHASE2)
- Opioid, HIV and Immune System (PHASE4)
- HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer (EARLY_PHASE1)
- A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant (PHASE1)
- Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer (PHASE1, PHASE2)
- Testing the SurVaxM Vaccine for Lung Cancer Prevention (PHASE2)
- IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence (PHASE2)
- Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Biological vaccine CI brief — competitive landscape report
- Biological vaccine updates RSS · CI watch RSS
- Inmunotek S.L. portfolio CI